Skip to main content
Pipeline Bio Ecosystem Analytics Report · July 2026 Mapping the capabilities Australian life-sciences Providers offer on a fee-for-service basis: the specialist work that can be outsourced. 258 Providers · 5,944 fee-for-service capabilities catalogued Authors: James Cooney and Nenad Sejic · Source: Pipeline Bio Database, snapshot July 2026

Explore the interactive report

The full report with interactive sunburst, tree map, and Level 3–4 category explorers for all thirteen taxonomy categories.

​
Abstract

This report explores the Australian life-sciences Provider landscape, drawn from the Pipeline Bio Database. As of July 2026, the Database holds 258 Providers publishing 5,944 fee-for-service capabilities, mapped across the Capability Taxonomy. The figures in this report reflect fee-for-service capabilities; the Platform is also expanding to list collaboration and licensing capabilities, which sit outside these counts. Fee-for-service R&D capability in Australia spans the full research and development value chain, with particular depth in clinical delivery and pharmaceutical manufacturing in Victoria and New South Wales, and a Provider base that skews towards specialist organisations. This report maps that distribution across the eight core categories of the value chain and considers what it means for biotechs and Providers.

​
Background

Biotech, medtech, pharmaceutical, and research teams routinely depend on external Providers for the specialist work that sits between an idea and an approved product. The challenge in Australia is not always whether a capability exists, but whether it can be found, evaluated, and engaged. That difficulty has a structural cause: the country’s scientific-services landscape has never been mapped in a consistent, quantitative way. Austrade has published a useful high-level Life Sciences Industry Capability Report, but it lacks the granularity a research team needs to pinpoint a specific capability for a project. Provider discovery therefore happens through informal networks, ad hoc searches, and word of mouth, leaving a sector where a team can struggle to identify a Provider it needs even when that Provider already exists. The Pipeline Bio Platform addresses that gap with a Directory of Providers and by cataloguing capability against a structured Capability Taxonomy. This report uses that catalogue to ask three foundational questions: how much capability exists nationally and how it is distributed across scientific categories; where that capability physically sits across the States and Territories; and how it is organised across the Providers that hold it. A clearer map of Australian capability reduces friction for international companies evaluating Australia, improves the use of existing infrastructure, and shows the sector where national capability clusters or runs shallow.

​
Methods

The data source is the Pipeline Bio Provider Database, captured as a snapshot in July 2026. Data was collected by Pipeline Bio from publicly available information — Provider websites, brochures, and interviews — or entered into the Database by Providers themselves. The Capability Taxonomy is a four-level hierarchy that moves from broad areas of activity to increasingly specific ones. It comprises 13 Level 1, 77 Level 2, 434 Level 3, and 541 Level 4 categories. Because branches are subdivided to different depths, and Providers vary in how finely they itemise a given body of work, capability counts are best interpreted alongside Provider participation. The figures below focus on eight core categories of the scientific research and development value chain: Clinical; Pharmaceutical Manufacturing, CMC & Testing; Preclinical; Post-Approval, Market Access & Lifecycle; Regulatory Affairs; Data, Statistics & Software; Quality Systems, Compliance & Assurance; and Medical Device Capabilities. The other five categories — Supply Chain & Logistics; Facilities, Equipment & Engineering; Financial & RDTI; Legal & IP; Organisational & Corporate — cover professional, operational, and corporate capabilities that sit outside the scientific value chain.
Every capability listed on the Platform is tagged as fee-for-service, collaboration, or licensing. The figures throughout this report reflect fee-for-service capabilities only.

​
Results: capability coverage

Figure 1 — Summary of the Pipeline Bio Database. The Database holds 258 Australian Providers publishing 5,944 fee-for-service capabilities. 36.2% of all capabilities sit within the top two Level 1 categories, and 49.6% of Providers operate across three or more Level 1 categories. Together the eight core categories hold 4,523 capabilities, of which the two largest account for 47.6%.

​
Capabilities, Providers, and density by core category

Figure 2.1 — Capability fingerprint across the eight core categories.
Figure 2.2 — Unique Providers active in each core category.
Figure 2.3 — Density: capabilities per active Provider, by core category. The eight-category mean density is 7.3 capabilities per active Provider. Pharmaceutical Manufacturing, CMC & Testing is the densest category, closely followed by Clinical. Clinical also has the widest Provider participation, with 108 Providers.

​
Level 2 composition of the largest categories

Figure 3 — Level 2 categories within each core category, sized by capability count. At Level 3, Clinical & Research Data Management houses the most capabilities (100), followed by Drug Product Formulation Development (93), Regulatory Strategy Development & Roadmap (88), and Development & Scientific Advisory (86). The thirty most-served Level 3 categories account for 28.7% of all catalogued capabilities. At Level 4, the most-served category is Clinical Data Management (43), followed by Regulatory Consulting & Advice (34), Planning & Support (24), and Study Report Writing and Compliance Auditing & Consulting (21 each). These thirty Level 4 categories account for 7.8% of all capabilities, and 20.6% of the 2,239 core capabilities catalogued to full Level 4 depth.
Figure 4.1 — The 30 most-served Level 3 categories.
Figure 4.2 — The 30 most-served Level 4 categories.

​
Results: geographic distribution

Among the 209 Providers with at least one core capability, presence is concentrated in Victoria and New South Wales.
Figure 5.1 — Core-capable Providers by State.
Figure 5.2 — Core-category capabilities by State.
Providers operating in more than one State or Territory are counted in each jurisdiction, so the columns sum to more than 209 Providers and more than 4,523 capabilities. The eight jurisdictions together hold 6,145 State-level listings.
Victoria and New South Wales account for 68% of state-level capability listings, compared with 61% of Provider listings. The largest individual cells are Clinical in Victoria (577 capabilities) and Clinical in New South Wales (501). Clinical has the greatest depth overall, with 1,593 State-level listings, and is the largest core category in Victoria, New South Wales, Queensland, and South Australia. Pharmaceutical Manufacturing, CMC & Testing is the largest category in Western Australia and Tasmania; Post-Approval, Market Access & Lifecycle is the largest in the ACT and Northern Territory. Coverage is notably narrow in places. In Tasmania, 113 capabilities sit in Pharmaceutical Manufacturing, CMC & Testing, more than half the State’s core total. Medical Device Capabilities is the smallest core category at 285 State-level listings, mostly in Victoria (176) and New South Wales (75); Western Australia, the ACT, and the Northern Territory record none in the current dataset.
Figure 5.3 — Capabilities by State and core category.

​
Results: Provider structure

​
Capabilities by Company Category

Figure 6 — Capabilities by Company Category and core category. Company Category is a Provider’s own description and is distinct from the capability categories of the taxonomy; a Provider may carry more than one, so capabilities offered by multi-category Providers appear under more than one row. Consultancies are the most evenly distributed type.

​
Specialist versus generalist

Of the 209 Providers with at least one core Level 1 capability:
Figure 7 — Specialist and generalist Providers.

​
Coverage across the four R&D stages

Grouping the value chain into Preclinical, Clinical, Manufacturing, and Post-Market:
Figure 8 — Provider coverage across the four R&D stages. The remaining 22 Providers are core-capable but do not fall into any of the four defined stages, because their activity sits entirely in cross-cutting categories such as Regulatory Affairs, Data, Statistics & Software, and Quality Systems, which support the development pipeline rather than representing a discrete stage within it.

​
Discussion

Measured by catalogued capabilities, Clinical and Pharmaceutical Manufacturing, CMC & Testing together hold 47.6% of all core capability, centring in Victoria and New South Wales. The prominence of the Clinical category carries through to the number of distinct Providers, consistent with Australia’s strength in clinical-stage R&D. With 34 active Providers, Medical Device Capabilities is the category where teams outsourcing R&D may have the least choice, and where single-source dependency risk may be highest. The Provider base is specialist-leaning: a little over half of core-capable Providers work in one or two core categories, and only 22 span all four R&D stages end to end. For most outsourcing, that may mean assembling several focused Providers rather than relying on one broad Provider. Capability density should be read as a catalogue-structure measure rather than a direct measure of market depth or category strength. Assessing capabilities within each Level 1 category against those of other nations, or against a defined set of all plausible capabilities within that category, would be informative analyses to conduct, and will be the focus of future reports. A question raised is whether the distribution reflects deliberate, demand-led prioritisation or genuine capability gaps. As a supply-side map, the dataset counts what Providers offer, not what biotech and medtech teams are looking for. A thin category may mark an undersupplied area, where demand exists but local capability does not — the case that should be addressed, because unmet domestic demand tends to be met offshore. Alternatively, it may reflect a category where demand has been too thin to sustain more Providers, in which case supply-side intervention risks creating capacity that demand does not support. A future study will incorporate demand-side data so that supply gaps can be understood with more context. Continued efforts to map Australia’s life-sciences R&D capability will support the sector’s growth and competitiveness, and organising the ecosystem into a structured Directory of Providers and Capability Taxonomy is what makes that capability discoverable.

​
Supplementary figures

The interactive report includes explorers for the full Capability Taxonomy beneath each of the thirteen Level 1 categories. Expand any category below to explore its full Level 2 to Level 4 structure. Click a tile to list its Level 3 categories, then expand any row to reveal Level 4 detail.

​
References

  1. Austrade. Life Sciences Industry Capability Report. Australian Government.
  2. Pipeline Bio. Directory of Providers. Pipeline Bio Pty Ltd.
  3. Pipeline Bio. Capability Taxonomy. Pipeline Bio Pty Ltd.
Source for all figures: Pipeline Bio Database, July 2026. Inclusion in the Database does not assess the quality, suitability, regulatory status, capacity, or performance of a capability, nor constitute an endorsement of any Provider.